Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00001465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Disease Process of Lymphangioleiomyomatosis

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 382 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. Re-verified, no change to tracked fields
  4. Eligibility criteria expanded, about 1 word
  5. 3 versions Re-verified since Aug 26, 2026, no change to tracked fieldsv376-v378
Show 43 earlier versionsHide 43 earlier versions
  1. Eligibility criteria expanded, about 152 wordsv375 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  2. Study Status, Study Description, Eligibilityv374
  3. 41 versions Re-verified since Feb 13, 2025, no change to tracked fieldsv333-v373
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals. ...
Trial Details
NCT Number NCT00001465
Lead Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Conditions Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
Enrollment 2,000 participants
Start Date
Updated on ClinicalTrials.gov